Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update.

Rasha KaddouraBassant OrabiAmar M Salam

Published in: Journal of drug assessment (2020)

The use of PCSK9 monoclonal antibodies in the treatment of dyslipidemia is currently recommended to achieve risk-specific LDL-C goal to reduce adverse CV events. Future results of the ongoing research might expand their clinical generalizability to broader patient populations.

Keyphrases

low density lipoprotein
case report
current status
emergency department
adverse drug
replacement therapy
electronic health record